Renal functional and surgical outcomes after robot-assisted partial nephrectomy for hilar vs non-hilar tumors: Trifecta and pentafecta evaluation
World Journal of Nephrology · 25.09.2026 · 15 (3)
DOI: 10.5527/wjn.119576 ↗Kurz gefasst
Fachartikel in der Zeitschrift World Journal of Nephrology, online erschienen am 25.09.2026. Verfasst von Takuto Hara und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Kobe University Graduate School of Medicine, Kobe 6500017, Hyōgo, Japan. supermarimo85@carp.kobe-u.ac.jp. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND Robot-assisted partial nephrectomy (RAPN) is well-suited for managing complex renal tumors, including those located in the renal hilum. However, studies directly comparing RAPN outcomes for hilar and non-hilar tumors, particularly in terms of comprehensive measures, such as trifecta and pentafecta, are still limited. AIM To evaluate whether tumor location in the renal hilum independently influences surgical and renal functional outcomes after RAPN, as assessed by trifecta and pentafecta criteria. METHODS This single-center retrospective cohort study evaluated outcomes of RAPN for hilar and non-hilar renal tumors treated from April 2016 to June 2023. Eligible patients had tumors ≤ 7 cm, no metastasis, and at least one year of follow-up. Propensity score matching was applied. Primary endpoints were trifecta and pentafecta achievement. All procedures were performed under ischemia without early unclamping. Multivariate logistic regression identified predictors of outcome achievement. RESULTS Of 350 patients, 324 met the inclusion criteria, consisting of 60 hilar and 264 non-hilar tumors. Trifecta achievement was similar between hilar (63.3%) and non-hilar groups (64.0%), with no significant differences in ischemia time, positive margins, or major complications. Pentafecta achievement rates were also similar (20.0% hilar vs 14.0% non-hilar, P = 0.237). Multivariate analysis identified R score, N score, and L score as predictors of pentafecta non-achievement. Surgeon experience and hilar tumor presence were predictors of pentafecta achievement. Hilar tumor location was not an independent determinant in the propensity-matched analysis, suggesting that the adjustment methods and sample size may have influenced the results. CONCLUSION RAPN achieved comparable trifecta and pentafecta outcomes for hilar and non-hilar tumors, supporting its viability for complex hilar tumors when appropriate patient selection and surgical experience are ensured.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, Kobe University Graduate School of Medicine, Kobe 6500017, Hyōgo, Japan. supermarimo85@carp.kobe-u.ac.jp.
- Department of Urology, Kobe University Graduate School of Medicine, Kobe 6500017, Hyōgo, Japan.
Zitieren
APA
Hara, T., Suzuki, K., Wakita, N., Okamura, Y., Ueki, H., Bando, Y., Terakawa, T., Hyodo, Y., Chiba, K., Teishima, J., Yao, A., & Miyake, H. (2026). Renal functional and surgical outcomes after robot-assisted partial nephrectomy for hilar vs non-hilar tumors: Trifecta and pentafecta evaluation. World Journal of Nephrology, 15(3). https://doi.org/10.5527/wjn.119576
Vancouver
Hara T, Suzuki K, Wakita N, Okamura Y, Ueki H, Bando Y, et al. Renal functional and surgical outcomes after robot-assisted partial nephrectomy for hilar vs non-hilar tumors: Trifecta and pentafecta evaluation. World Journal of Nephrology. 2026;15(3). doi:10.5527/wjn.119576
BibTeX
@article{Hara2026,
author = {Hara, Takuto and Suzuki, Kotaro and Wakita, Naoto and Okamura, Yasuyoshi and Ueki, Hideto and Bando, Yukari and Terakawa, Tomoaki and Hyodo, Yoji and Chiba, Koji and Teishima, Jun and Yao, Akihisa and Miyake, Hideaki},
title = {Renal functional and surgical outcomes after robot-assisted partial nephrectomy for hilar vs non-hilar tumors: Trifecta and pentafecta evaluation},
journal = {World Journal of Nephrology},
year = {2026},
volume = {15},
number = {3},
doi = {10.5527/wjn.119576}
}
EUVIMED